cytochrome c oxidase subunit 6C pseudogene 14Genealiases: []
Q-omics provides the consensus-scored COX6CP14 profile across patient tissues and cancer cell-line models. COX6CP14 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in TGCT. Among the 18 cancer types available for tumor–normal comparison, COX6CP14 is differentially expressed in 3, with the highest sampling consensus in ESCA. Additionally, COX6CP14 RNA expression shows 7,479 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight TGCT, ESCA, and GBM as cancer lineages where COX6CP14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for COX6CP14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes COX6CP14 survival associations across molecular data types. COX6CP14 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible COX6CP14 RNA expression–survival associations across cancer types. High COX6CP14 expression shows unfavorable associations in TGCT, ESCA, BLCA and THYM, but favorable associations in COAD and MESO. The TGCT Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify TGCT as the clearest survival context for COX6CP14 RNA expression.
This table summarizes COX6CP14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in ESCA for RNA.
This table ranks reproducible tumor–normal expression differences for COX6CP14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. COX6CP14 shows higher tumor expression in ESCA, STAD and LIHC. The ESCA box plot shows higher COX6CP14 RNA expression in tumor versus normal tissue (log2 FC = +0.415, t-test p = .023).
This table shows molecular features associated with COX6CP14 in patient tissues and cancer cell lines. In patient samples, COX6CP14 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
